Theory and strategy for Pneumococcal vaccines in the elderly. Issue 2 (1st February 2016)

• Record Type: Journal Article
• Authors: Namkoong, Ho; Ishii, Makoto; Funatsu, Yohei; Kimizuka, Yoshifumi; Yagi, Kazuma; Asami, Takahiro; Asakura, Takanori; Suzuki, Shoji; Kamo, Testuro; Fujiwara, Hiroshi; Tasaka, Sadatomo; Betsuyaku, Tomoko; Hasegawa, Naoki
• Is Part Of: Human vaccines & immunotherapeutics. Volume 12:Issue 2(2016)
• Page Start: 336
• Page End: 343
• Publication Date: 2016-02-01
• Subjects: aging -- elderly -- pneumococcal vaccines -- pneumococcal conjugate vaccine -- pneumococcal polysaccharide vaccine -- pneumococcal diseases -- senescence; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2015.1075678
• Languages: English
• ISSNs: 2164-5515

Abstract

Abstract : Pneumonia is the fourth-leading cause of death globally, and Streptococcus pneumoniae is the most important causative pathogen. Because the incidence of pneumococcal diseases is likely to increase with the aging society, we should determine an optimal strategy for pneumococcal vaccination. While consensus indicates that 23-valent pneumococcal polysaccharide vaccine prevents invasive pneumococcal diseases (IPD), its effects on community-acquired pneumonia (CAP) remain controversial. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) was released. The latest clinical study (CAPiTA study) showed that PCV13 reduced vaccine-type CAP and IPD. Based on these results, the Advisory Committee on Immunization Practices recommended initial vaccination with PCV13 for the elderly. Scientific evidence regarding immunosenescence is needed to determine a more ideal vaccination strategy for the elderly with impaired innate and adaptive immunity. Continuing research on the cost effectiveness of new vaccine strategies considering constantly changing epidemiology is also warranted.